Key Drivers
- Gross Margin
- Cash Burn
- High Leverage
AIAI Summary
TVTX now looks more like a commercial-stage growth story than a speculative biotech, but the investment case depends on FILSPARI and the new FSGS label expansion scaling fast enough to convert 98% gross margins and 55.6% revenue growth into positive cash flow before leverage, burn, and the new convertible debt drive dilution risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Cash Burn
- •High Leverage
TVTX has excellent 98% gross margins and solid liquidity, but persistent operating losses, rising cash burn, and a leveraged balance sheet make the stock fundamentally stretched.
Price Behavior
Key Price Behavior Insights:
- •Support holding
- •Momentum fading
- •Range resistance
Over the last month, TVTX has recovered constructively but choppily, with $42-ish support still holding, $44.50-$44.90 acting as resistance, and a break below support likely opening a retest of $40-$41.
Sharp pullback from $44.55 on 2026-05-13 to $42.59 on 2026-05-15 signals fading momentum and volatility
Sentiment & News
Key News Insights:
- •Earnings miss
- •FILSPARI momentum
- •Note refinancing
Travere Therapeutics missed Q1 2026 earnings and revenue, but strong FILSPARI momentum, FDA progress, and a new $475M convertible note deal suggest the market focus remains on growth and capital structure improvements.
The news is likely modestly supportive overall, as clinical and commercial progress appears to outweigh the near-term earnings miss and financing dilution concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings